The 31st National High School Manga Championship (Manga Koshien)
12.4.2022 09:00:00 EEST | Business Wire | Press release
What is Manga Koshien?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220408005170/en/
Flyer (Graphic: Business Wire)
It is a competition where teams of high school students compete on manga creations. This competition started in 1992 and celebrated its 30th anniversary last year. Since 2014, schools from overseas also started entering the competition, and we are seeing approximately 300 schools participating each year from Japan and abroad.
Teams of three to five students each work together to draw a one-page manga in accordance with a specified theme for the preliminaries. Those who manage to pass the preliminaries gather in Kochi during summer for the main round.
Teams in the main round (semifinals, revival round, finals) stand a chance to win the grand prize and other awards. This means prize money, drawing materials, and more! In addition, during the main round, talented students may even be scouted by major manga publishers and perhaps debut as professionals!
1. Preliminary Round Theme
- Space debris (Uchuu Gomi)
- ∞ Infinity (Mugen)
Draw and submit a one-page manga of either one of these themes.
Manga Koshien Website: https://mangaoukoku-tosa.jp/manga-koshien31/
2. Eligibility
- Japan and overseas senior high school students or similar (approximately 15 to 18 years of age)
- Only one team per school is allowed to participate.
3. Guidelines for the Preliminary Round Entries
- Entries should be submitted online at https://mangaoukoku-tosa.jp/manga-koshien31/
- The manga must be of B4 size (257mm x 364mm, in any orientation).
- The manga must be produced jointly by all students registered in the application form.
4. Timeline
(1) Preliminary Round (Online)
- Deadline: Tuesday, May 31st, 2022, 24:00 (JST)
- Judging: Tuesday, June 14th, 2022
- Chosen schools: 33 schools (30 from Japan, 3 from overseas)
(2) Main Round (Kochi Prefecture, Japan)
- Participants: 33 schools that passed the preliminary round
- Date: Saturday, 30th, and Sunday, 31st, July 2022
- Venue: Kochi Jibasan Center
- Participation fee: JPY 30,000 (per person)
*The participation fee will cover the participants’ air ticket, accommodation, etc.
*Travel arrangements will be made by the event organizer
5. Main Round Judges
- All 6 Preliminary Round Judges
-
Guest Judges
Fujimaki Tadatoshi (Famous works: Kuroko no Basuke, Robot x Laserbeam)
Yukimoto Shuuji (Famous works: Kemo Life, Shark Girl)
*For more details, please refer to the Implementation Outline at the following
URL: https://mangaoukoku-tosa.jp/manga-koshien31/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005170/en/
Contact information
In-charge: Yasuaki Okamatsu, Risa Matsumoto
Manga Kingdom Tosa Promotional Committee
(within the Manga Kingdom Tosa Office)
TEL: +81-(0)88-823-9711 FAX: +81-(0)88-823-9296
Email: 140201@ken.pref.kochi.lg.jp
Website: https://mangaoukoku-tosa.jp/manga-koshien31/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 05:00:00 EEST | Press release
Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated over the three years through 2028. The amount to be awarded to Helical Fusion will be announced following the formal grant
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release
ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom